#USA #Boston #Huntington's Disease #Skyhawk Therapeutics #SKY-0515

Skyhawk Therapeutics Releases Twelve-Month cUHDRS Findings

Skyhawk Therapeutics, a pioneering clinical-stage biotechnology firm, has revealed significant outcomes from its clinical trial concerning SKY-0515, an oral therapy aimed at treating Huntington's disease (HD). This twelve-month analysis from the trial's phase 1/2 study outlines encouraging trends across various performance metrics, indicating a potential milestone in Huntington's treatment options.

Overview of the Findings

Published recently at the European Academy of Neurology, the findings suggest that participants receiving SKY-0515 experienced positive changes across four critical subcomponents of the composite Unified Huntington's Disease Rating Scale (cUHDRS). These include Total Functional Capacity (TFC), Total Motor Score (TMS), Symbol Digit Modalities Test (SDMT), and Stroop Word Reading Test (SWRT).

Key Results

• - Total Functional Capacity (TFC): Patients exhibited a mean improvement of +0.07, contrasting sharply with the anticipated decline of -0.87 delineated through historical data reference from Enroll-HD.
• - Total Motor Score (TMS): Results showed a mean change of -2.00 compared to expected worsening of 2.21 points.
• - Symbol Digit Modalities Test (SDMT): A favorable stabilization was noted with a mean change of -0.19, outperforming the expected decline of -1.78.
• - Stroop Word Reading Test (SWRT): The mean change was +3.44, while the expected outcome suggested a deterioration of -3.13.

Physician and Patient Perspectives

In addition to these metrics, data from the Clinical Global Impression (CGI) and Patient Global Impression (PGI) surveys over the twelve-month period provided compelling insights. Remarkably, both physicians and patients reported no disease progression, with 65% of participants and 50% of physicians reflecting perceived improvements.

Treatment Impact

The investigational SKY-0515 also exhibited significant effects on mutant huntingtin protein (mHTT) levels, achieving up to a 69% reduction in the bloodstream alongside a 26% drop in PMS1 mRNA. These proteins play a pivotal role in the neurological decline characteristic of Huntington's disease. Sergey Paushkin, Skyhawk's Head of R&D, expressed his optimism regarding the findings, emphasizing the promising prospect of offering patients a long-awaited daily oral treatment that may substantially improve their quality of life.

Study Background

The phase 1/2 trial consists of three segments: the first two sections evaluated the safety and pharmacokinetics of SKY-0515 in healthy volunteers, while the third phase is a randomized, double-blind, placebo-controlled study that assesses two dose levels in early-stage Huntington's patients over a longer duration. Currently, over 175 participants are involved across various global locations, highlighting Skyhawk's commitment to advancing this critical research.

Next Steps

Skyhawk's innovative approach doesn't stop at SKY-0515, as its proprietary SKYSTAR® platform continues to develop other RNA modulation therapies targeting rare neurological diseases lacking effective treatments. The company has ambitious plans to expand its clinical development programs by the end of 2027, promising brighter futures for those impacted by complex conditions like Huntington's disease.

In conclusion, Skyhawk Therapeutics stands at the forefront of Huntington's disease research, and the promising data from the SKY-0515 study not only reflects hope for thousands affected by this challenging condition but also underscores the potential for breakthroughs in treatment methodologies that may redefine patient experiences and outcomes in the near future.